Bellicum Pharmaceuticals Inc. CEO Thomas Farrell told BioWorld Today that the snag, albeit short-term, met by Juno Therapeutics Inc. jolted some out of "perhaps a good deal of denial about safety as an issue" in chimeric antigen receptor (CAR) T-cell therapy.